Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
NCT ID: NCT00108108
Last Updated: 2012-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
26 participants
INTERVENTIONAL
2005-04-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCD122
HCD122
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCD122
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Refractory or relapsed disease
* Prior treatment with fludarabine
* Male or Female
* \>18 years of age
Exclusion Criteria
* Clinically significant cardiac dysfunction or other significant organ dysfunction
Additional eligibility criteria apply that will be reviewed with potential study subjects at the site.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
XOMA (US) LLC
INDUSTRY
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Novartis
Role: STUDY_CHAIR
Novartis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California San Diego StudyCoordinator:CHCD122A2101
La Jolla, California, United States
St. Francis Cancer Research Foundation
Beech Grove, Indiana, United States
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Div Of HematologicMalignancies
Baltimore, Maryland, United States
OSU Medical Center/Arthur G. James Cancer Hospital StudyCoordinator:CHCD122A2101
Columbus, Ohio, United States
MD Anderson Cancer Center/University of Texas Dept of MD Anderson CancerCent
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHCD122A2101
Identifier Type: -
Identifier Source: org_study_id